D'Afonseca Vívian, Arencibia Ariel D, Echeverría-Vega Alex, Cerpa Leslie, Cayún Juan P, Varela Nelson M, Salazar Marcela, Quiñones Luis A
Centro de Investigación de Estudios Avanzados del Maule (CIEAM), Vicerrectoría de Investigación y Postgrado, Universidad Católica del Maule, Talca, Chile.
Centro de Biotecnología de los Recursos Naturales (CenBio), Facultad de Ciencias Agrarias y Forestales, Universidad Católica del Maule, Talca, Chile.
Cancer Inform. 2020 May 25;19:1176935120922154. doi: 10.1177/1176935120922154. eCollection 2020.
Prognostic markers for cancer can assist in the evaluation of survival probability of patients and help clinicians to assess the available treatment modalities. Gallbladder cancer (GBC) is a rare tumor that causes 165 087 deaths in the world annually. It is the most common cancer of the biliary tract and has a particularly high incidence in Chile, Japan, and northern India. Currently, there is no accurate diagnosis test or effective molecular markers for GBC identification. Several studies have focused on the discovery of genetic alterations in important genes associated with GBC to propose novel diagnosis pathways and to create prognostic profiles. To achieve this, we performed data-mining of GBC in public repositories, harboring 133 samples of GBC, allowing us to describe relevant somatic mutations in important genes and to propose a genetic alteration atlas for GBC. In our results, we reported the 14 most altered genes in GBC: , and in samples from Japan, the United States, Chile, and China. Missense mutations are common among these genes. The annotations of many mutations revealed their importance in cancer development. The observed annotations mentioned that several mutations found in this repository are probably oncogenic, with a putative loss-of-function. In addition, they are hotspot mutations and are probably linked to poor prognosis in other cancers. We identified another 11 genes, which presented a copy number alteration in gallbladder database samples, which are , and . The findings reported here can help to detect GBC cancer through the development of systems based on genetic alterations, for example, the development of a mutation panel specifically for GBC diagnosis, as well as the creation of prognostic profiles to accomplish the development of GBC and its prevalence.
癌症的预后标志物有助于评估患者的生存概率,并帮助临床医生评估可用的治疗方式。胆囊癌(GBC)是一种罕见的肿瘤,每年在全球导致165087人死亡。它是胆道最常见的癌症,在智利、日本和印度北部发病率特别高。目前,尚无用于胆囊癌识别的准确诊断测试或有效的分子标志物。多项研究聚焦于发现与胆囊癌相关的重要基因中的基因改变,以提出新的诊断途径并创建预后概况。为实现这一目标,我们在公共数据库中对胆囊癌进行了数据挖掘,该数据库包含133份胆囊癌样本,这使我们能够描述重要基因中的相关体细胞突变,并提出胆囊癌的基因改变图谱。在我们的研究结果中,我们报告了胆囊癌中14个改变最多的基因: ,以及来自日本、美国、智利和中国样本中的 。错义突变在这些基因中很常见。许多突变的注释揭示了它们在癌症发展中的重要性。观察到的注释表明,在这个数据库中发现的几个突变可能是致癌的,具有假定的功能丧失。此外,它们是热点突变,可能与其他癌症的不良预后有关。我们还鉴定出另外11个基因,它们在胆囊数据库样本中呈现拷贝数改变,这些基因是 ,以及 。此处报告的研究结果有助于通过基于基因改变开发系统来检测胆囊癌,例如,开发专门用于胆囊癌诊断的突变检测板,以及创建预后概况以实现胆囊癌的发展及其流行情况。